Drug-eluting stents in acute myocardial infarction: Is science catching up with practice?

JAMA

Volumn 293, Issue 17, 2005, Pages 2154-2156

  Cohen, Mauricio G ^a   Ohman, E Magnus ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; PACLITAXEL; RAPAMYCIN; TIROFIBAN;

ACUTE HEART INFARCTION; ANGIOGRAPHY; BARE METAL STENT; CLINICAL PRACTICE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY STENT; COST OF ILLNESS; DRUG ELUTING STENT; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART REINFARCTION; HIGH RISK PATIENT; HUMAN; PACLITAXEL ELUTING STENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RESTENOSIS; RISK FACTOR; SIROLIMUS ELUTING STENT; ST SEGMENT ELEVATION; THROMBOSIS; TREATMENT OUTCOME; UNITED STATES; DRUG DELIVERY SYSTEM; HEART INFARCTION; NOTE; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; DRUG DELIVERY SYSTEMS; HUMANS; MYOCARDIAL INFARCTION; PACLITAXEL; SIROLIMUS; STENTS;

EID: 17844364619     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.293.17.2154     Document Type: Editorial

References (24)

1. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-1323.
2. Stone GW, Ellis SC, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221-231.
3. US Food and Drug Administration. CYPHER™ Sirolimus-eluting Coronary Stent on RAPTOR® Over-the-Wire Delivery System or RAPTORRAIL® Rapid Exchange Delivery System-P020026. April 24, 2003. Available at: http://www.fda.gov/cdrh/pdf2/p020026.html. Accessed April 2, 2005.
4. US Food and Drug Administration. FDA Public Health Web Notification: Information for Physicians on Sub-acute Thromboses (SAT) and Hypersensitivity Reactions with Use of the Cordis CYPHER™ Coronary Stent. October 29, 2003. Available at: http://www.fda.gov/cdrh/safety/cypher.html. Accessed April 2, 2005.
5. Kandzari DE, Roe MT, Ohman EM, et al. Frequency, patterns and predictors of drug eluting stent utilization in patients with high-risk non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE quality improvement initiative. Am J Cardiol. In press.
6. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364:1519-1521.
7. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful Implantation of drug-eluting stents. JAMA. 2005;293:2126-2130.
8. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004;109:701-705.
9. Kerner A, Gruberg L, Kapeliovich M, Grenadier E. Late stent thrombosis after implantation of a sirolimus-eluting stent. Catheter Cardiovasc Interv. 2003;60:505-508.
10. Valgimigli M, Percoco G, Malagutti P, et al; STRATEGY Investigators. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA. 2005;293:2109-2117.
11. Grines CL, Cox DA, Stone GW, et al; Stent Primary Angioplasty in Myocardial Infarction Study Group. Coronary angioplasty with or without stent implantation for acute myocardial infarction. N Engl J Med. 1999;341:1949-1956.
12. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002;346:957-966.
13. Kastrati A, Mehilli J, von Beckerath N, et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA. 2005;293:165-171.
14. Kastrati A. Paclitaxel-eluting stent versus sirolimus-eluting stent for the prevention of restenosis in diabetic patients with coronary artery disease (ISAR-DIABETES). Presented at: 2005 Scientific Session of the American College of Cardiology; March 6, 2005; Orlando, Fla.
15. Morice MC. Eight-month outcome of the Reality Study: a prospective randomized multi-center head-to-head comparison of the sirolimus-eluting stent (Cypher) and the paclitaxel-eluting stent (Taxus). Presented at: 2005 Scientific Session of the American College of Cardiology; March 6, 2005; Orlando, Fla.
16. Stone GW. Outcomes of the polymer-based, paclitaxel-eluting Taxus stent in complex lesions: principal, clinical, and angiographic results from the Taxus-V pivotal randomized trial. Presented at: 2005 Scientific Session of the American College of Cardiology; March 6, 2005; Orlando, Fla.
17. Lemos PA, Saia F, Hofma SH, et al. Short- and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents-for patients with acute myocardial infarction. J Am Coll Cardiol. 2004;43:704-708.
18. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001;344:1888-1894.
19. Batchelor WB, Tolleson TR, Huang Y, et al. Randomized comparison of platelet inhibition with abciximab, tirofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Circulation. 2002;106:1470-1476.
20. Kabbani SS, Aggarwal A, Terrien EF, DiBattiste PM, Sobel BE, Schneider DJ. Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. Am J Cardiol. 2002;89:647-650.
21. Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions: the task force for percutaneous coronary interventions of the European society of cardiology. Eur Heart J. 2005;26:804-847.
22. Montalescot G, Borentain M, Payot L, Collet JP, Thomas D. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. JAMA. 2004;292:362-366.
23. Popma JJ, Berger P, Ohman EM, Harrington RA, Grines C, Weitz JI. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:576S-599S.
24. Kandzari DE, Hasselblad V, Tcheng JE, et al. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. Am Heart J. 2004;147:457-462.